Alzheimer Dementia
 

NeuroResearch Clinics, Inc.

  AMA Category 1
  Continuing Medical Education
   
   
   
   
 
HOME PAGE
 
The Diseases
 
Attention Deficit ADD ADHD
Anxiety / Panic Attacks
Alzheimer Dementia
Depression
Suicide
Fibromyalgia
Insomnia
Migraine headaches
Parkinson's Disease
Trichotillomania
Obsessive Compulsive Disorder-OCD
 
Antidepressants
Brain Damage
Neurotransmitter Depletion
Protocols
Side Effects
neurotransmitter testing
 
University Writings About NeuroResearch Clinics
 
Neurotoxins
Technical Guide
Narrated Slide Shows
Public Interviews
Med Ed Web Site
DBS Labs Web Site
Faba Bean Warning
Webinars
Sitemap
Contact Us
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alzheimer Dementia-research
Alzheimer Dementia-research
Alzheimer Dementia-research
Alzheimer Dementia-research
 

 

Sunset Redfish Bay Fort Myers, Florida photo by Marty L. Hinz, MD  
  Alzheimer Dementia
Alzheimer Dementia

Alzheimer Dementia

Contact us or find a caregiver using this approach.
 

Alzheimer Dementia

Written by: Marty L. Hinz, MD
President Clinical Research
NeuroResearch Clinics, Inc.  
Cape Coral, Florida USA Research Office  
 

  Real treatment of Alzheimer Dementia, where brain function is truly restored has eluded medicine. The NeuroResearch Clinics approach produces excellent treatment results in Alzheimer Dementia patients.

Alzheimer Dementia

  The NeuroResearch Clinics approach to treatment of Alzheimer Dementia patients with Alzheimer Dementia involves neurotransmitter optimization of the master neurotransmitters of the brain serotonin, dopamine, norepinephrine and epinephrine. These neurotransmitters directly and indirectly control virtually every function in the brain and body. NeuroResearch Clinics uses 5-HTP, tyrosine, levodopa, and cysteine guided by neurotransmitter testing as indicted to restore brain function and get other symptoms associated with Alzheimer Dementia under control. Most patients show significant improvement of cognitive brain function. 15% to 20% of Alzheimer Dementia patients achieve profound restoration of  brain function. Please, read the case studies in the right brown colored column, these were written by medical doctors (MDs) based on medical care experiences. For restoration of the brain in Alzheimer Dementia patients neurotransmitter optimization is in a league of its own, beyond results seen with any prescription drug in the past.

  Its no secret, NeuroResearch Clinics uses the nutrients 5-HTP, tyrosine, levodopa, and cysteine to treat medical patients in order to get these results. Proper use of these simple ingredients in medical treatment is not simple. From time to time a patient will say, "Why do I want to take that, I can go to a health food store and buy it?" People off the street buying in a health food store is like going to an art store and buying a bunch of oil paints then going home and expecting to paint like a mater artist even though there was no previous painting experience. These nutrients have tremendous potential due to their chemical properties. This potential is only fully realized in the hands of the trained professional using neurotransmitter testing. Treatment is not just giving a nutrient pill, it is the whole medical management approach doctors are trained in to insure that that treatment is on track in order to get symptoms under control.

Alzheimer Dementia
- Alzheimer Dementia home page

- Case study #1

- Case study #2

- Case study #3

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Alzheimer Dementia

SYMPTOMS

  While deterioration of brain function takes the spot light in Alzheimer Dementia patient treatment there are many other problems that can be active, including:

  • Sleep patterns, Many patients suffer from abnormal sleep patterns, up during the night wandering around or sleeping during the day. With serotonin and dopamine optimization normal sleep patterns are restored in the Alzheimer Dementia patient.

  • Inappropriate anger, aggression, or yelling out, is a problem with some patients suffering from Alzheimer Dementia. With serotonin and dopamine optimization inappropriate anger, aggression, or yelling out are controlled in the patient.

  • Agitation, many patients with this. This may take the form of mental or physical agitation. With serotonin and dopamine optimization agitation is controlled in the patient.

  • Depression is common in Alzheimer Dementia. Depression may display as an agitated depression. In medicine there is no drug that effectively controls depression in the elderly, with or without Alzheimer Dementia. With neurotransmitter optimization of serotonin and dopamine guided by neurotransmitter testing when indicated depression is controlled.

  • Anxiety, may be present. With neurotransmitter optimization of serotonin and dopamine guided by neurotransmitter testing as indicted, anxiety in the patient may be controlled.

  • Psychotic state is a significant problem with patients talking about and hearing or seeing things that are not there. With neurotransmitter optimization of serotonin and dopamine guided by neurotransmitter testing as indicated, the Alzheimer Dementia patient may experience control of inappropriate perceptions.

  • Restless Leg Syndrome is common, contributing greatly sleep disturbance which leads to exacerbation of cognitive problems. With neurotransmitter optimization of serotonin and dopamine guided by neurotransmitter testing as indicted, Restless Leg Syndrome in the Alzheimer Dementia can be controlled.

The Peer Reviewed Research of NeuroResearch Clinics

  The neurotransmitter treatment research findings of NeuroResearch Clinics have not been ignored. The University of Minnesota Medical School is writing a series of papers on the neurotransmitter testing research of NeuroResearch Clinics. The first of a series of papers by University of Minnesota Medical School based on the neurotransmitter testing research of NeuroResearch was published in "NeuroPsychiatric Disease and Treatment" May 1, 2009. Ingrid Kohlstadt, MD of Johns Hopkins in her new medical text book released February 7, 2009 included a chapter on depression written by Marty L. Hinz, MD  President Clinical Research NeuroResearch Clinics outlining in depth the proper use of amino acids and neurotransmitter testing in treatment of depression.

University of Minnesota Medical School neurotransmitter testing paper on the research of NeuroResearch Clinics.

 

The medical text book chapter on depression written by Marty L. Hinz, MD-Ingrid Kohlstadt, MD editor-Johns Hopkins released February, 7, 2009

Alzheimer Dementia

 

WHAT CAUSES

Alzheimer Dementia?

Elevation of neurotransmitter levels, guided by neurotransmitter testing, reveals excellent results in  Alzheimer patients suffering with Dementia. Review of neurotransmitter testing prior to treatment reveals that patients with Alzheimer Dementia, as a group, have virtually the same neurotransmitter levels as those that do not. Therefore low levels of neurotransmitters is not the cause of Alzheimer Dementia.

The primary cause of Alzheimer Dementia appears to be brain damage. The leading cause is neurotoxic damage. Just as with Parkinson's Disease patients elevating neurotransmitter levels restores flow of electricity in the brain compensating for brain damage, restoring normal function, and relieving symptoms.

 

Alzheimer Dementia Links

Alzheimer Dementia organization

Alzheimer Dementia Medline

Alzheimer Dementia Mayo

Alzheimer Dementia Foundation

Alzheimer Dementia news

 

 
If you need a medical speaker for AMA Category I CME call NeuroResearch Clinics, Inc.
NeuroResearch Clinics, Inc. only deals with and provides information to licensed health care professionals.
 
keyz keyb
 
Alzheimer Dementia